InsidersTradesSigma
Follow the 九洲药业 stock price and the full management transaction log of the company, a publicly traded company based in China. Shares trade on the CN market, under the oversight of SSE / SZSE (CSRC). Operating in the Health Care sector, 九洲药业 has recorded 1 reports. Market capitalisation: €13bn. The latest transaction was reported on 8 July 2024 (Purchase). Among the most active insiders: 沙裕杰. All data is accessible without an account.
1
Insider Decl.
n/a
Thresholds
€24,481
1 ops.
Buy Volume
n/a
n/a
Sell Volume
7Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 4,695 of 29,064 companies
69.3
score / 100
Value70
Quality69
FCF yld8.9%
Earn yld5.6%
EV/EBITDA9.7x
ROE7.3%
Gross mgn37%
Net mgn13%
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 8 July 2024
关于 九洲药业
九洲药业是一家在上海证券交易所上市的健康和制药公司。它专注于创新药物的研发和生产。